TOI & CareMore care model showcases better cancer care at lower cost
By Nikita Chaurasia  Date: 2019-09-09

TOI & CareMore care model showcases better cancer care at lower cost
  • The study registered CareMore patients that were newly diagnosed with hematologic and solid malignancies from November 2016 to September 2018.
     
  • The cancer care model which is value-based used LHWs, they are non-physician community members who have obtained specialized training to help patient navigation and care.

The Oncology Institute, (TOI) and Stanford University’s School of Medicine as well as CareMore Health together announced the outcome from a study; improving community capacity to provide value-based cancer care during the end-of-life.

The study examined the effect of interference of having lay health workers, LHWs, for cancer care during the end-of-life. Precisely, the study evaluated the use of healthcare at life’s last month and its effect on financial burden and quality care for patients.

The study registered CareMore patients that were newly diagnosed with hematologic and solid malignancies from November 2016 to September 2018. The study matched results to a controlled set of all patients detected with cancer in the year earlier to intervention.

The cancer care model which is value-based used LHWs, they are non-physician community members obtained specialized training to help in patient navigation and care. The study found no difference in living between the control groups of patients, while the patients getting the value-based care witnessed greater quality along with cancer care at end-of-life.

The latter group of patients had 40% lesser inpatient admissions, 75% lesser visits to emergency department at the last month of their life, increased hospice use of 45% was witnessed, 40% fewer acute care service deaths and median totalized healthcare costs reduced by 25% from diagnosis till death.

Assistant prof. of medicine at Stanford University School for Medicine and the head investigator of the study, Manali Patel, MD, MPH stated that due to this trial the care model which is value-based developed by the group at Stanford and applied by the Oncology Institute is connected with significant enhancements in patient care at the life’s end.

 

Source credit: https://www.businesswire.com/news/home/20190907005023/en/Study-Demonstrates-Significantly-Quality-Cancer-Care-Costs

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fractyl raises series E funding of USD 55 million for diabetes cure
Fractyl raises series E funding of USD 55 million for diabetes cure
By Nikita Chaurasia

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes. As per the trusted sources, the capital will be invested on mass-b...

Nokia Corp. partners with IISc to improve telecommunication solutions
Nokia Corp. partners with IISc to improve telecommunication solutions
By Nikita Chaurasia

Finnish multinational telecommunications giant Nokia Corporation has recently made it to the headlines after entering into a joint venture agreement with IISc (Indian Institute of Science) to launch the Nokia CoE (Centre of excellence) for Networked ...

Motorola acquires Pelco Inc. to expand its video security services
Motorola acquires Pelco Inc. to expand its video security services
By Nikita Chaurasia

Chicago-based telecommunication company, Motorola Solutions Inc., has made it to the headlines through its acquisition of Pelco Inc. from Transom Capital Group for $110 million dollars. For those uninitiated, Pelco Inc. is a security and surveillanc...

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
By Nikita Chaurasia

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures a...

Boehringer Ingelheim acquires GST to expand stem cell capabilities
Boehringer Ingelheim acquires GST to expand stem cell capabilities
By Nikita Chaurasia

Boehringer Ingelheim, a leader in pharmaceutical products, has recently made it to the headlines by acquiring Belgium-based veterinary biotech firm, Global Stem cell Technology (GST). According to reliable sources, the collaboration with GST will al...